Clinical trials: Moderate Chronic Plaque Psoriasis
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.
- Trial name
- NCT03724292
- Testing
- VTP-43742
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Chronic Plaque Psoriasis
Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis
It is a phase IV multicentric, placebo-controlled, clinical trial investigating the efficacy and safety of acitretin combined to efalizumab in the therapy of chronic plaque psoriasis.
- Trial name
- CobAcE (NCT00707070)
- Testing
- efalizumab plus acitretin
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universita di Verona
Moderate to Severe Chronic Plaque Psoriasis
This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).
This is an open-label, 2-arm parallel-group study in normal healthy subjects to evaluate pharmacokinetics, safety, tolerability of Bmab 1200 -autoinjector (AI) after single subcutaneous injection (45 mg) in comparison with Bmab…
- Trial name
- NCT06738277
- Testing
- Bmab 1200 (Biosimilar Ustekinumab)
- Where
- India
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Biocon Biologics UK Ltd
Psoriasis
Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and effectiveness of CNDO 201Trichuris suis ova (TSO) for the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT01836939
- Testing
- TSO 2500, TSO 7500
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mark Lebwohl
Healthy Volunteers, Mild to Moderate Psoriasis
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of…
- Trial name
- NCT05965089
- Testing
- AX-202
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Arxx Therapeutics
Chronic Plaque Psoriasis
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly…
- Trial name
- NCT07337434
- Testing
- Methotrexate, Apremilast
- Where
- Pakistan
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Syeda Sana Zaman
Moderate to Severe Psoriasis
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
This is a single-center, open-label, pilot study. A total of 18 subjects will be enrolled in this 6 month study to evaluate whether the response to intralesional alefacept injections prior to the standard course of…
- Trial name
- NCT00678470
- Testing
- Intralesional Alefacept
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco